OUR SCIENTIFIC POSTERS AND EXHIBITOR HOSTED SESSIONS
We invite you to join us at our poster and exhibitor hosted sessions, you can view all details in this page.
If you wish to receive a copy of all our presentations, fill out the form below and you will get them in one email right after the end of SOT 2024.
And if you wish to meet with our safety assessment experts, just book a meeting by clicking the button on the right!
EXHIBITOR HOSTED SESSIONS
Navigating Drug Discovery's New Horizon with a Predictive Safety Continuum
Presented by: Ilaria Sartori, Evotec and Paul Walker, Cyprotex
Session Description: Embark on a transformative journey with Evotec and Cyprotex's Predictive Safety Continuum, revolutionizing drug discovery safety. Through advanced predictive analytics and cutting-edge technologies, we proactively assess safety, employing high-content screening, toxicogenomics, and computational models. Our integrated, science-driven approach minimizes drug attrition, ensuring comprehensive understanding and optimal candidate selection for successful drug development.
Date and Time: Monday, March 11: 10:30 AM–11:30 AM
Location: Salt Palace Convention Center - Room: 155 E
De-risking drug discovery with Toxicogenomics
Presented by: Paul Walker PhD, Cyprotex/Evotec
Accelerating Drug Discovery using omics-based AI safety predictions
Presented by: Kevin Contrepois PhD, AstraZeneca
Session Description: Two presentations on the latest advances in Cell Painting, Toxicogenomics (TGx) and Proteomics to de-risk drug induced liver injury (DILI) and cardiotoxicity liabilities in drug discovery projects. Demonstrating the valuable insights towards decision making and increasing the likelihood of drug discovery success. In addition, advanced technologies such as predictive omics approaches provide additional value by gaining in-depth mechanistic understanding of both DILI and cardiotoxic effects.
Date and Time: Tuesday, March 12: 12:00 Noon–1:00 PM
Location: Salt Palace Convention Center - Room: 155 E
Using Integration to Drive Efficiency and Reduce Risk in Drug Development
Presented by: Josh Gillum, Evotec
Session Description: Outsourcing drug development in the biotech and pharmaceutical sectors is costly, resource-intensive, and laden with risks. Companies seeking new therapies often adopt a traditional model, engaging multiple vendors for the scientific data required to complete a clinical trial initiation dossier. This places the entire burden of risk and resource provision on the sponsoring company, compounding the complexities and expenses of drug development.
Date and Time: Wednesday, March 13: 10:30 AM–11:30 AM
Location: Salt Palace Convention Center - Room: 155 E
PLATFORM SESSION
A Multiparametric In Vitro assay and High-Throughput RNA Sequencing for Cardiotoxicity Risk Assessment and Prediction of Mechanisms
Presented by: Steve Madden
Abstract Number: 2041
Session: Advancements in Cardiotoxicity Assessment
Date and Time: 3/12/2024 1:00:00 PM to 3/12/2024 2:30:00 PM
Location: Room 250 D‚ Salt Palace Convention Center
Presentation Time during the Session (US Mountain Time): 3/12/2024 2:00:00 PM–3/12/2024 2:15:00 PM
POSTER PRESENTATIONS
Validation of a New Genotoxicity Approach for Food Additives
Presenting Author: Thomas Kaczka
Session Date and Time: 11 March at 11:45 am to1:45 pm MST
Session Location: Salt Palace Convention Center, ToxExpo Hall
Increased food demand due to a growing global population incentivizes the need to identify and develop safer and more effective food additives as required by regulators such as the FDA and EFSA. In vitro genotoxicity studies are required by these organisations of which assays such as the Comet assay, present lack of consistency in the literature regarding incubation time and analysis. The possible identification of DNA-damage-inducing food additives using automated high content screening with robust data analysis would support de-risking food additives.
Establishment of a High Throughput Endocrine Disruptor Screening Panel of Assays for Rapid Testing of Chemicals
Presenting Author: You Feng
Session Date and Time: 12 March at 2:15 pm to 4:15 pm MST
Session Location: Salt Palace Convention Center, ToxExpo Hall
The endocrine system is comprised of hormones released by internal glands and their target receptors on distant organs. Hormone receptors, including Androgen Receptor (AR), Estrogen Receptor (ER) and Thyroid Hormone Receptor (TR), are a wide family of proteins that bind to specific hormones and activate a broad range of signaling pathways, such as growth, metabolism, development, reproduction, and response to stress. Since these hormone receptors interact with their ligands with high specificity and high affinity, very low concentrations of hormone can induce significant cellular responses. Endocrine disruptors, either natural or man-made, can interfere with the normal actions of hormones and affect the endocrine system, causing serious health problems such as cancer, birth defects, and developmental disorders.
Traditional Endocrine Disruptor Screening Assays use radioactively labeled materials or animal models with high cost and low efficiency. Here we utilized commercially available assays to establish a panel of 384-well high throughput cell-based hormone activation assays and in vitro hormone receptor binding assays with luminescence or fluorescence polarization end points with rapid turnaround time.
An AI Approach to Drug-Induced Liver Injury Risk: Prediction of Safe Maximum Doses from Toxicogenomic Profiles
Presenting Author: Paul Walker
Session Date and Time: 13 March at 11:45 am to 13 March 1:45 om MST
Session Location: Salt Palace Convention Center, ToxExpo Hall
Drug-induced liver injury (DILI) is a major cause of attrition during the later drug development stages. Often, this leads to the termination of the program after significant investments have been made. Hence, there is a strong need for methods which a) rank drug candidates by their DILI risk as early as possible in the development program and b) estimate a safe dose for subsequent clinical trials.
In Vitro Methodology to Detect Chemically Reactive Metabolites
Presenting Author: Ralf Geiben Lynn
Session Date and Time: 13 March at 11:45: am to 1:45 pm MST
Session Location: Salt Palace Convention Center, ToxExpo Hall
Drug-induced liver injury (DILI) remains a leading cause of drug attrition within the drug discovery and development process alongside clinical observations and potential market withdrawal. The cause of DILI is often multifaceted and complex and often includes a multitude of often interconnected cellular events, such as transporter inhibition, mitochondrial dysfunction, and chemically reactive metabolite (CRM) formation, that ultimately culminate in hepatotoxicity. The cytochrome P450 (CYP450) superfamily of metabolic enzymes are crucial for the excretion of xenobiotics from the body. In many cases, those xenobiotics that harbour potent biological activity are metabolised into daughter chemicals with lower potency than their parent. However, in certain instances the addition of chemical groups can induce the formation of a CRM capable of interacting with cellular macromolecules, ultimately inducing adverse cellular events and consequently liver damage. This process of compound bioactivation can in part be mitigated by the Glutathione (GSH)-conjugation system that is capable of binding with CRM and forming GSH-adducts, preventing adverse effects induced by CRM formation. The resultant depletion of cellular GSH can itself, however, result in downstream adverse events, such as the increase in reactive oxygen species (ROS) and oxidative damage of DNA, proteins, and lipids.
